Contact Us
Drug Search Results
More Filters [+]

Foslinanib

Alternative Names: foslinanib, trx-818, trx818, trx 818
Latest Update: 2023-12-05
Latest Update Note: Clinical Trial Update

Product Description

CVM-1118 (Foslinanib) is a new synthetic small molecule with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors. In particular, CVM-1118 possesses the novel mechanism of inhibiting a unique structure known as vasculogenic mimicry (VM), which is associated with metastasis and drug-induced resistance in malignant tumors. (Sourced from: https://www.trx.com.tw/en/portfolio-items/cvm-1118/)

Mechanisms of Action: Angiogenesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TaiRx
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Foslinanib

Countries in Clinic: Taiwan

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Hepatocellular Carcinoma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CVM-008

P2

Recruiting

Hepatocellular Carcinoma

2025-09-30

57%
CVM-005

P2

Active, not recruiting

Neuroendocrine Carcinoma|Pancreatic Cancer|Neuroendocrine Tumors

2024-09-30

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions